TD Cowen Boosts Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $28.00

Adaptive Biotechnologies (NASDAQ:ADPT) had its price target upped by analysts at TD Cowen from $25.00 to $28.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s price objective suggests a potential upside of 22.24% from the company’s previous close.

A number of other brokerages have also issued reports on ADPT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Morgan Stanley raised their price target on Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. BTIG Research boosted their target price on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. Guggenheim lifted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. cut their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Adaptive Biotechnologies Stock Up 1.5%

ADPT traded up $0.35 on Thursday, reaching $22.91. The company had a trading volume of 1,846,627 shares, compared to its average volume of 2,309,452. Adaptive Biotechnologies has a 1 year low of $9.96 and a 1 year high of $23.88. The stock has a market capitalization of $3.67 billion, a PE ratio of -69.39 and a beta of 2.07. The stock has a 50-day moving average price of $19.05 and a 200-day moving average price of $16.56.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.20) EPS. As a group, analysts expect that Adaptive Biotechnologies will post -0.47 earnings per share for the current fiscal year.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Sharon Benzeno sold 154,768 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52. Following the completion of the sale, the insider owned 221,278 shares of the company’s stock, valued at approximately $4,677,816.92. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 492,400 shares of the business’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total value of $10,778,636.00. Following the transaction, the insider directly owned 812,058 shares of the company’s stock, valued at $17,775,949.62. This trade represents a 37.75% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,305,787 shares of company stock valued at $27,828,563. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Adaptive Biotechnologies

Hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $28,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. Assetmark Inc. raised its position in Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth $51,000. Finally, Strive Financial Group LLC bought a new position in shares of Adaptive Biotechnologies in the 4th quarter worth $52,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: BTIG raises target and reiterates Buy: BTIG Research increased its price target from $24 to $25 and maintained a “Buy” rating, implying further upside from recent trading levels. Benzinga analyst price target report
• Positive Sentiment: Second-quarter revenue exceeded expectations: Adaptive Biotechnologies reported $71.55 million in revenue, above the $65.44 million consensus estimate, with year-over-year growth of 21.5%. The company also reported an adjusted loss of $0.10 per share versus the $0.13 expected loss, improving from a $0.17 loss a year earlier. Zacks second-quarter earnings report
• Positive Sentiment: Brokerage sentiment remains constructive: The company has a consensus “Moderate Buy” rating, with five Buy ratings, one Hold and one Sell. Institutional investors own approximately 99% of outstanding shares, indicating substantial professional-investor participation.
• Neutral Sentiment: Earnings-call details are being reviewed: The Q2 2026 conference call transcript may provide additional information on commercial momentum, partnerships and the outlook for Adaptive’s immune-repertoire sequencing business. Q2 2026 earnings call transcript
• Negative Sentiment: Profitability remains a concern: Despite the adjusted earnings beat, Adaptive Biotechnologies remains unprofitable, with a reported negative net margin and negative return on equity. One earnings summary cited a $0.25 per-share GAAP loss, highlighting the difference between adjusted and GAAP results. Adaptive Biotechnologies second-quarter financial results
• Negative Sentiment: Insider selling adds a cautionary signal: Director Harlan Robins sold 492,400 shares worth approximately $10.8 million, reducing his position by 37.75%. The sale was made under a pre-arranged Rule 10b5-1 plan, which lessens—but does not eliminate—the signaling concern. Adaptive Biotechnologies insider sale report

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.